Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Mar 10;3(3):CD011649.
doi: 10.1002/14651858.CD011649.pub2.

Management of people with intermediate-stage hepatocellular carcinoma: an attempted network meta-analysis

Davide Roccarina  1 , Avik Majumdar  1 , Douglas Thorburn  1 , Brian R Davidson  2 , Emmanuel Tsochatzis  1 , Kurinchi Selvan Gurusamy  2
Affiliations
Review

Management of people with intermediate-stage hepatocellular carcinoma: an attempted network meta-analysis

Davide Roccarina et al. Cochrane Database Syst Rev. .

Abstract

Background: There is significant uncertainty in the treatment of intermediate-stage hepatocellular carcinoma which is defined by the Barcelona Clinic Liver Cancer (BCLC) as hepatocellular carcinoma stage B with large, multi-nodular, Child-Pugh status A to B, performance status 0 to 2, and without vascular occlusion or extrahepatic disease.

Objectives: To assess the comparative benefits and harms of different interventions used in the treatment of intermediate-stage hepatocellular carcinoma (BCLC stage B) through a network meta-analysis and to generate rankings of the available interventions according to their safety and efficacy. However, we found only one comparison. Therefore, we did not perform the network meta-analysis, and we assessed the comparative benefits and harms of different interventions versus each other, or versus placebo, sham, or no intervention (supportive treatment only) using standard Cochrane methodology.

Search methods: We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, Embase, Science Citation Index Expanded, World Health Organization International Clinical Trials Registry Platform, and randomised clinical trials registers to September 2016 to identify randomised clinical trials on hepatocellular carcinoma.

Selection criteria: We included only randomised clinical trials, irrespective of language, blinding, or publication status, in participants with intermediate-stage hepatocellular carcinoma, irrespective of the presence of cirrhosis, size, or number of the tumours (provided they met the criteria of intermediate-stage hepatocellular carcinoma), of presence or absence of portal hypertension, of aetiology of hepatocellular carcinoma, and of the future remnant liver volume. We excluded trials which included participants who had previously undergone liver transplantation. We considered any of the various interventions compared with each other or with no active intervention (supportive treatment only). We excluded trials which compared variations of the same intervention: for example, different methods of performing transarterial chemoembolisation.

Data collection and analysis: We used standard methodological procedures expected by Cochrane. We calculated the hazard ratio (HR) with 95% confidence intervals (CI) using both fixed-effect and random-effects models based on available-participant analysis with Review Manager. We assessed risk of bias according to Cochrane, controlled risk of random errors with Trial Sequential Analysis using Stata, and assessed the quality of the evidence using GRADE.

Main results: Three randomised clinical trials, including 430 participants, met the inclusion criteria for this review; however, data from two trials with 412 participants could be included in only one primary outcome (i.e. mortality). All three trials were at high risk of bias. All three trials included supportive care as cointervention. The comparisons included in the two trials reporting on mortality were: systemic chemotherapy with sorafenib versus no active intervention; and transarterial chemoembolisation plus systemic chemotherapy with sorafenib versus transarterial chemoembolisation alone. The trials did not report the duration of follow-up; however, it appeared that the participants were followed up for a period of about 18 to 30 months. The majority of the participants in the trials had cirrhotic livers. The trials included participants with intermediate-stage hepatocellular carcinoma arising from viral and non-viral aetiologies. The trials did not report the portal hypertension status of the participants. The mortality was 50% to 70% over a median follow-up period of 18 to 30 months. There was no evidence of difference in mortality at maximal follow-up between systemic chemotherapy versus no chemotherapy (hazard ratio 0.85, 95% CI 0.60 to 1.18; participants = 412; studies = 2; I2 = 0%; very low quality evidence). A subgroup analysis performed by stratifying the analysis by the presence or absence of transarterial chemoembolisation as cointervention did not alter the results. None of the trials reported on serious adverse events other than mortality, health-related quality of life, recurrence of hepatocellular carcinoma, or length of hospital stay. One of the trials providing data was funded by the pharmaceutical industry, the other did not report the source of funding, and the trial with no data for the review was also funded by the pharmaceutical industry. We found two ongoing trials.

Authors' conclusions: Currently, there is no evidence from randomised clinical trials that people with intermediate-stage hepatocellular carcinoma would benefit from systemic chemotherapy with sorafenib either alone or when transarterial chemoembolisation was used as a cointervention (very low quality evidence). We need high-quality randomised clinical trials designed to measure differences in clinically important outcomes (e.g. all-cause mortality or health-related quality of life).

PubMed Disclaimer

Conflict of interest statement

This report is independent research funded by the National Institute for Health Research (NIHR Cochrane Programme Grants, 13/89/03 ‐ Evidence‐based diagnosis and management of upper digestive, hepato‐biliary, and pancreatic disorders). The views expressed in this publication are those of the authors and not necessarily those of the National Health Service (NHS), the NIHR, or the Department of Health.

DR has no financial disclosures. AM has no financial disclosures. DT received funding from Astellas for his attendance at the International Liver Transplantation Society meeting in 2014. He received GBP 25,000 from Boston Scientific to fund a clinical research fellow in 2013. There are no other financial disclosures to report. BD has no financial disclosures. ET has participated in advisory boards for AstraZeneca and ViiV Healthcare. KG has no financial disclosures.

Figures

1
1
Study flow diagram.
2
2
Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.
3
3
Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
4
4
Trial Sequential Analysis of mortality at maximal follow‐up: based on an alpha error of 2.5%, power of 90% (beta error of 10%), a relative risk reduction (RRR) of 20%, the control group proportion (Pc) of 50%, and observed heterogeneity (0%), the a priori information size (APIS) was 2011. As shown in the figure, the cumulative Z‐curve (blue line) do not cross any of trial sequential monitoring boundaries (red lines). They do not cross the conventional alpha boundary of 2.5% (green line) either.
1.1
1.1. Analysis
Comparison 1: Interventions for hepatocellular carcinoma, Outcome 1: Mortality at maximal follow‐up
See this image and copyright information in PMC

Update of

  • doi: 10.1002/14651858.CD011649

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

References to studies included in this review

Bruix 2012 {published data only}
    1. Bruix J, Raoul JL, Sherman M, Mazzaferro V, Bolondi L, Craxi A, et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. Journal of hepatology 2012;57(4):821-9. [PMID: ] - PubMed
    1. Bruix J, Raoul JL, Sherman M, Shan M, Lentini G, Nadel A. Efficacy and safety of sorafenib in patients with hepatocellular carcinoma (HCC): subanalysis of sharp trial based on Barcelona clinic liver cancer (BCLC) stage. Journal of Hepatology 2009;50(Suppl 1):S28.
    1. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. New England Journal of Medicine 2008;359(4):378-90. - PubMed
de Stefano 2015 {published data only}
    1. Stefano G, Iodice V, Signoriello G, Scognamiglio U, Farella N. Efficacy and safety of combined sequential treatment with RFA and sorafenib in patients with HCC in intermediate stage ineligible for TACE: a prospective randomized open study. Journal of Hepatology 2015;62:S852-3.
    1. Stefano G, Scognamiglio U, Iodice V, Farella N, Simeone E, Montesarchio V. Efficacy and safety of combined sequential treatment with radiofrequency ablation and sorafenib in patients with hepatocellular carcinoma in intermediate stage ineligible for TACE: a prospective randomized open study. Annals of Oncology 2015;26:103-4.
Lencioni 2016 {published data only}
    1. Han G, Lencioni R, Llovet JM, Tak WY, Yang J, Guglielmi A, et al. Sorafenib plus transarterial chemoembolization with DC bead (DEB-TACE) for patients from Asian countries with intermediate-stage HCC: SPACE study results. Hepatology International 2013;7:S616.
    1. Lencioni R, Llovet JM, Han G, Tak WY, Yang J, Guglielmi A, et al. Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: the SPACE trial. Journal of Hepatology 2016;64(5):1090-8. - PubMed
    1. Lencioni R, Zou J, Leberre M, Meinhardt G, Voliotis D, Bruix J, et al. Sorafenib (SOR) or placebo (PL) in combination with transarterial chemoembolization (TACE) for intermediate-stage hepatocellular carcinoma (SPACE). Journal of Clinical Oncology 2010;28(Suppl 15):26.

References to studies excluded from this review

Abdelaziz 2015 {published data only}
    1. Abdelaziz AO, Nabeel MM, Elbaz TM, Shousha HI, Hassan EM, Mahmoud SH, et al. Microwave ablation versus transarterial chemoembolization in large hepatocellular carcinoma: prospective analysis. Scandinavian Journal of Gastroenterology 2015;50(4):479-84. - PubMed
Anonymous 1995 {published data only}
    1. Anonymous. A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. Groupe d'etude et de traitement du carcinome hepatocellulaire. New England Journal of Medicine 1995;332(19):1256-61. - PubMed
Arai 2010 {published data only}
    1. Arai Y, Inaba Y, Yamamoto T, Kanai F, Aramaki T, Tanaka T, et al. A randomized phase II study of TSU-68 in patients (pts) with hepatocellular carcinoma (HCC) treated by transarterial chemoembolization (TACE). Journal of Clinical Oncology Conference 2010;28(15 Suppl 1):Abstract: 4030.
Bartolozzi 1995 {published data only}
    1. Bartolozzi C, Lencioni R, Caramella D, Vignali C, Cioni R, Mazzeo S, et al. Treatment of large HCC: transcatheter arterial chemoembolization combined with percutaneous ethanol injection versus repeated transcatheter arterial chemoembolization. Radiology 1995;197(3):812-8. - PubMed
Becker 2005 {published data only}
    1. Becker G, Soezgen T, Olschewski M, Laubenberger J, Blum HE, Allgaier HP. Combined TACE and PEI for palliative treatment of unresectable hepatocellular carcinoma. World Journal of Gastroenterology 2005;11(39):6104-9. - PMC - PubMed
Bruix 1998 {published data only}
    1. Bruix J, Llovet JM, Castells A, Montana X, Bru C, Ayuso MC, et al. Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: results of a randomized, controlled trial in a single institution. Hepatology (Baltimore, Md.) 1998;27(6):1578-83. - PubMed
Chen 2002 {published data only}
    1. Chen MS, Li JQ, Zhang YQ, Lu LX, Zhang WZ, Yuan YF, et al. High-dose iodized oil transcatheter arterial chemoembolization for patients with large hepatocellular carcinoma. World Journal of Gastroenterology 2002;8(1):74-8. - PMC - PubMed
Chen 2007 {published data only}
    1. Chen XP, Hu DY, Zhang ZW, Zhang BX, Chen YF, Zhang WG, et al. Role of mesohepatectomy with or without transcatheter arterial chemoembolization for large centrally located hepatocellular carcinoma. Digestive Surgery 2007;24(3):208-13. - PubMed
Cheng 2004 {published data only}
    1. Cheng SQ, Wu MC, Chen H, Shen F, Yang JH, Cong WM, et al. Transcatheter hepatic arterial chemoembolization and thymosin alpha1 in postoperative treatment of hepatocellular carcinoma. Zhonghua Zhong Liu Za Zhi 2004;26(5):305-7. - PubMed
Cheng 2008 {published data only}
    1. Cheng BQ, Jia CQ, Liu CT, Fan W, Wang QL, Zhang ZL, et al. Chemoembolization combined with radiofrequency ablation for patients with hepatocellular carcinoma larger than 3 cm: a randomized controlled trial. (Retraction in: JAMA 2009; 301(18):1931). JAMA 2008;299(14):1669-77. - PubMed
Choi 2014 {published data only}
    1. Choi C, Koom WS, Kim TH, Yoon SM, Kim JH, Lee HS, et al. A prospective phase 2 multicenter study for the efficacy of radiation therapy following incomplete transarterial chemoembolization in unresectable hepatocellular carcinoma. International Journal of Radiation Oncology 2014;90(5):1051-60. - PubMed
Chow 2002 {published data only}
    1. Chow PK, Tai BC, Tan CK, Machin D, Win KM, Johnson PJ, et al. High-dose tamoxifen in the treatment of inoperable hepatocellular carcinoma: a multicenter randomized controlled trial. Hepatology (Baltimore, Md.) 2002;36(5):1221-6. - PubMed
DeAngelis 2009 {published data only}
    1. DeAngelis CD, Fontanarosa PB. Chemoembolization combined with radiofrequency ablation for patients with hepatocellular carcinoma larger than 3 cm: a randomized controlled trial. (Retraction of: JAMA 2008; 299(14):1669-77). JAMA 2009;301(18):1931. - PubMed
Doffoel 2008 {published data only}
    1. Doffoel M, Bonnetain F, Bouche O, Vetter D, Abergel A, Fratte S, et al. Multicentre randomised phase III trial comparing tamoxifen alone or with transarterial lipiodol chemoembolisation for unresectable hepatocellular carcinoma in cirrhotic patients. European Journal of Cancer 2008;44(4):528-38. - PubMed
El‐Kady 2013 {published data only}
    1. El-Kady NM, Esmat G, Mahmoud EH, Darweesh SK, Mahmoud SH, Elagawy WA. Hypertonic saline-enhanced radiofrequency versus chemoembolization sequential radiofrequency in the treatment of large hepatocellular carcinoma. European Journal of Gastroenterology & Hepatology 2013;25(5):628-33. - PubMed
Ferrari 2004 {published data only}
    1. Ferrari FS, Stella A, Gambacorta D, Magnolfi F, Fantozzi F, Pasquinucci P, et al. Treatment of large hepatocellular carcinoma: comparison between techniques and long term results. Radiologia Medica 2004;108(4):356-71. - PubMed
Fischman 2014 {published data only}
    1. Fischman AM, Lewis SC, Patel R, Kim E, Nowakowski FS, Lookstein RA, et al. Prospective, randomized study of coiling vs surefire infusion system in Y-90: clinical outcomes in HCC patients-subgroup analysis of safety and efficacy from the COSY trial. Cardiovascular and Interventional Radiology 2014;37(2 Suppl 1):S252.
Gallo 2006 {published data only}
    1. Gallo C, De Maio E, Di Maio M, Signoriello G, Daniele B, Pignata S, et al. Tamoxifen is not effective in good prognosis patients with hepatocellular carcinoma. BMC Cancer 2006;6:196. - PMC - PubMed
Gish 2009 {published data only}
    1. Gish RG, Gordon SC, Nelson D, Rustgi V, Rios I. A randomized controlled trial of thymalfasin plus transarterial chemoembolization for unresectable hepatocellular carcinoma. Hepatology International 2009;3(3):480-9. - PMC - PubMed
Golfieri 2014 {published data only}
    1. Golfieri R, Giampalma E, Renzulli M, Cioni R, Bargellini I, Bartolozzi C, et al. Randomised controlled trial of doxorubicin-eluting beads vs conventional chemoembolisation for hepatocellular carcinoma. British Journal of Cancer 2014;111(2):255-64. - PMC - PubMed
Hebbar 2015 {published data only}
    1. Hebbar M, Heurgue-Berlot A, Boige V, Malicot K, Bernard-Chabert B, Marcus C, et al. Randomized phase 2/3 trial of transcatheter arterial chemoembolization (TACE) plus sunitinib or placebo in patients with hepatocellular carcinoma (HCC) (PRODIGE 16/SATURNE study): results of the phase II part. European Journal of Cancer 2015;51:S434.
Hilgard 2008 {published data only}
    1. Hilgard P, Trojan J, Galle PR, Greten T, Erhardt A, Shan M, et al. Sorafenib improves survival in patients with hepatocellular carcinoma: results of a large multicenter, randomized, placebo-controlled phase III trial. Onkologie 2008;31(Suppl 1):78.
Hou 2009 {published data only}
    1. Hou YB, Chen MH, Yan K, Wu JY, Yang W. Adjuvant percutaneous radiofrequency ablation of feeding artery of hepatocellular carcinoma before treatment. World Journal of Gastroenterology 2009;15(21):2638-43. - PMC - PubMed
Huo 2003 {published data only}
    1. Huo TI, Huang YH, Wu JC, Lee PC, Chang FY, Lee SD. Comparison of percutaneous acetic acid injection and percutaneous ethanol injection for hepatocellular carcinoma in cirrhotic patients: a prospective study. Scandinavian Journal of Gastroenterology 2003;38(7):770-8. - PubMed
Iezzi 2013 {published data only}
    1. Iezzi R, Cesario V, Siciliani L, Campanale M, De Gaetano AM, Siciliano M, et al. Single-step multimodal locoregional treatment for unresectable hepatocellular carcinoma: balloon-occluded percutaneous radiofrequency thermal ablation (BO-RFA) plus transcatheter arterial chemoembolization (TACE). Radiologia Medica 2013;118(4):555-69. - PubMed
Inaba 2013 {published data only}
    1. Inaba Y, Kanai F, Aramaki T, Yamamoto T, Tanaka T, Yamakado K, et al. A randomised phase II study of TSU-68 in patients with hepatocellular carcinoma treated by transarterial chemoembolisation. European Journal of Cancer 2013;49(13):2832-40. - PubMed
    1. Kaneko S, Inaba Y, Kanai F, Aramaki T, Yamamoto T, Tanaka T, et al. Final results of a randomized phase II study of TSU-68 after transarterial chemoembolisation in Japanese patients with unresectable hepatocellular carcinoma. Annals of Oncology 2012;23:ix243.
Kolligs 2015 {published data only}
    1. Kolligs FT, Bilbao JI, Jakobs T, Inarrairaegui M, Nagel JM, Rodriguez M, et al. Pilot randomized trial of selective internal radiation therapy vs. chemoembolization in unresectable hepatocellular carcinoma. Liver International 2015;35(6):1715-21. - PubMed
Kudo 2002 {published data only}
    1. Kudo M, Chung H, Ogawa C, Fukuda N, Suetomi Y, Minami Y, et al. Radiofrequency ablation therapy combined with or without subsegmental lipiodol TAE for large hepatocellular carcinoma: a randomized prospective study. Hepatology (Baltimore, Md.) 2002;36(4):693A-4A.
Kudo 2014 {published data only}
    1. Kudo M, Han G, Finn RS, Poon RT, Blanc JF, Yan L, et al. Brivanib as adjuvant therapy to transarterial chemoembolization in patients with hepatocellular carcinoma: a randomized phase III trial. Hepatology (Baltimore, Md.) 2014;60(5):1697-707. - PubMed
Lammer 2010 {published data only}
    1. Lammer J, Malagari K, Vogl T, Pilleul F, Denys A, Watkinson A, et al. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovascular and Interventional Radiology 2010;33(1):41-52. - PMC - PubMed
Li 2009 {published data only}
    1. Li CX, Wu PH, Fan WJ, Huang JH, Zhang FJ, Zhang L, et al. Clinical effect of transcatheter arterial chemoembolization combined with high intensity focused ultrasound ablation in treatment of large hepatocellular carcinoma. National Medical Journal of China 2009;89(11):754-7. - PubMed
Li 2010 {published data only}
    1. Li CX, Zhang WD, Zhang R, Zhang LA, Wu PH, Zhang FJ. Therapeutic effects and prognostic factors in high-intensity focused ultrasound combined with chemoembolisation for larger hepatocellular carcinoma. European Journal of Cancer 2010;46(13):2513-21. - PubMed
Liu 2010 {published data only}
    1. Liu FY, Yu XL, Liang P, Wang Y, Zhou P, Yu J. Comparison of percutaneous 915 MHz microwave ablation and 2450 MHz microwave ablation in large hepatocellular carcinoma. International Journal of Hyperthermia 2010;26(5):448-55. - PubMed
Livraghi 2005 {published data only}
    1. Livraghi T, Meloni F, Frosi A, Lazzaroni S, Bizzarri M, Frati L, et al. Treatment with stem cell differentiation stage factors of intermediate-advanced hepatocellular carcinoma: an open randomized clinical trial. Oncology Research 2005;15(7-8):399-408. - PubMed
Llovet 2002 {published data only}
    1. Llovet JM, Real MI, Montana X, Planas R, Coll S, Aponte J, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002;359(9319):1734-9. - PubMed
Llovet 2007 {published data only}
    1. Llovet J, Mazzaferro V, Ricci S, Hilgard P, Raoul J, Zeuzem S, et al. Sorafenib improves survival in a large multi-center, randomized, placebo-controlled phase III trial in patients with hepatocellular carcinoma. European Journal of Cancer 2007;5(4 Suppl):261.
Lo 2002 {published data only}
    1. Lo CM, Ngan H, Tso WK, Liu CL, Lam CM, Poon RT, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology (Baltimore, Md.) 2002;35(5):1164-71. - PubMed
Malagari 2010 {published data only}
    1. Malagari K, Pomoni M, Kelekis A, Pomoni A, Dourakis S, Spyridopoulos T, et al. Prospective randomized comparison of chemoembolization with doxorubicin-eluting beads and bland embolization with beadblock for hepatocellular carcinoma. Cardiovascular and Interventional Radiology 2010;33(3):541-51. - PubMed
Meyer 2016 {published data only}
    1. Meyer T, Fox R, Ma YT, Ross PJ, James M, Strugess R, et al. TACE 2: a randomized placebo-controlled, double-blinded, phase III trial evaluating sorafenib in combination with transarterial chemoembolisation (TACE) in patients with unresectable hepatocellular carcinoma (HCC). Journal of Clinical Oncology Conference 2016;34:Abstract: 4018.
Mohnike 2013 {published data only}
    1. Mohnike K, Pech M, Seidensticker M, Seidensticker R, Bretschneider T, Schuette K, et al. A prospective randomized trial comparing HDR-brachytherapy and transarterial chemoembolization in hepatocellular carcinoma. Journal of Hepatology 2013;58:S50.
Morimoto 2010 {published data only}
    1. Morimoto M, Numata K, Kondou M, Nozaki A, Morita S, Tanaka K. Midterm outcomes in patients with intermediate-sized hepatocellular carcinoma: a randomized controlled trial for determining the efficacy of radiofrequency ablation combined with transcatheter arterial chemoembolization. Cancer 2010;116(23):5452-60. - PubMed
Morimoto 2011 {published data only}
    1. Morimoto M, Numata K, Kondo M, Nozaki A, Moriya S, Takizawa K. Long-term outcome in patients with intermediate-sized hepatocellular carcinoma: a randomized controlled trial to determine the efficacy of radiofrequency ablation combined with transcatheter arterial chemoembolization. Hepatology (Baltimore, Md.) 2011;54(4 Suppl):1366A-7A. - PubMed
Okusaka 2012 {published data only}
    1. Okusaka T, Kasugai H, Ishii H, Kudo M, Sata M, Tanaka K, et al. A randomized phase II trial of intra-arterial chemotherapy using SM-11355 (miriplatin) for hepatocellular carcinoma. Investigational New Drugs 2012;30(5):2015-25. - PMC - PubMed
Padia 2013 {published data only}
    1. Padia SA, Shivaram G, Bastawrous S, Bhargava P, Vo NJ, Vaidya S, et al. Safety and efficacy of drug-eluting bead chemoembolization for hepatocellular carcinoma: comparison of small-versus medium-size particles. Journal of Vascular & Interventional Radiology 2013;24(3):301-6. - PubMed
Pelletier 1998 {published data only}
    1. Pelletier G, Ducreux M, Gay F, Luboinski M, Hagege H, Dao T, et al. Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolization: a multicenter randomized trial. Groupe CHC. Journal of Hepatology 1998;29(1):129-34. - PubMed
Sansonno 2012 {published data only}
    1. Sansonno D, Lauletta G, Russi S, Conteduca V, Sansonno L, Dammacco F. Transarterial chemoembolization plus sorafenib: a sequential therapeutic scheme for HCV-related intermediate-stage hepatocellular carcinoma: a randomized clinical trial. Oncologist 2012;17(3):359-66. - PMC - PubMed
Sarin 1994 {published data only}
    1. Sarin SK, Sreenivas DV, Saraya A, Mehta S, Lahoti D, Malhotra V. Improved survival with percutaneous ethanol injection in patients with large hepatocellular carcinoma. European Journal of Gastroenterology and Hepatology 1994;6(11):999-1003.
Shi 2009 {published data only}
    1. Shi M, Chen J, Lin X, Chen M, Guo R, Li S, et al. Prospective randomized controlled study of transarterial chemoembolization with doxorubicin versus doxorubicin/lobaplatin/mitomycin combination for unresectable hepatocellular carcinoma. Chinese Journal of Clinical Oncology 2009;36(1):9-12.
Tanaka 2014 {published data only}
    1. Tanaka M, Ando E, Simose S, Hori M, Kuraoka K, Ohno M, et al. Radiofrequency ablation combined with transarterial chemoembolization for intermediate hepatocellular carcinoma. Hepatology Research 2014;44(2):194-200. - PubMed
Tang 2009 {published data only}
    1. Tang QH, Zhou JP, Fu SY, Zhou WP. Effect of preoperative transcatheter arterial chemoembolization for treatment of resectable large hepatocellular carcinoma: a clinical randomized controlled trial. Academic Journal of Second Military Medical University 2009;30(12):1379-84.
Ulbrich 2010a {published data only}
    1. Ulbrich G, Kolblinger C, Pinter M, Reiberger T, Ferlitsch A, Sieghart W, et al. AVATACE-1 trial: bevacizumab as inhibitor of collateral tumor-vessel-growth during transarterial chemoembolisation (TACE) for hepatocellular carcinoma - a double-blind, randomized, placebo-controlled pilot-trial. Hepatology (Baltimore, Md.) 2010;52:1159A-60A.
Ulbrich 2010b {published data only}
    1. Ulbrich G, Pinter M, Reiberger T, Ferlitsch A, Sieghart W, Peck-Radosavljevic M. Interim safety-analysis of the AVATACE-1 trial (bevacizumab as inhibitor of collateral tumor-vessel-growth during transarterial chemoembolisation (TACE) for hepatocellular carcinoma - a double-blind randomized placebo-controlled pilot-trial. Journal of Hepatology 2010;52:S54.
Wang 2007 {published data only}
    1. Wang YB, Chen MH, Yan K, Yang W, Dai Y, Yin SS. Quality of life after radiofrequency ablation combined with transcatheter arterial chemoembolization for hepatocellular carcinoma: comparison with transcatheter arterial chemoembolization alone. Quality of Life Research 2007;16(3):389-97. - PubMed
Wang 2014 {published data only}
    1. Wang LJ, Bu WZ, Chen H, Li JP, Ma SS, Song JL. Clinical study of TACE with or without antiviral treatment for hepatitis B virus related unresectable hepatocellular carcinoma. Chinese Journal of Cancer Prevention and Treatment 2014;21(20):1617-22.
Wu 1995 {published data only}
    1. Wu CC, Ho YZ, Ho WL, Wu TC, Liu TJ, P'Eng FK. Preoperative transcatheter arterial chemoembolization for resectable large hepatocellular carcinoma: a reappraisal. British Journal of Surgery 1995;82(1):122-6. - PubMed
Wu 1998 {published data only}
    1. Wu P, Li L, Zhang Y. Transcatheter arterial chemo-embolization combined with CT-guided percutaneous intratumoral injection of lipiodol-ethanol for the treatment of primary hepatocellular carcinoma. Zhonghua Zhong Liu za Zhi [Chinese Journal of Oncology] 1998;20(5):391-3. - PubMed
Xie 2015 {published data only}
    1. Xie ZR, Luo YL, Xiao FM, Liu Q, Ma Y. Health-related quality of life of patients with intermediate hepatocellular carcinoma after liver resection or transcatheter arterial chemoembolization. Asian Pacific Journal of Cancer Prevention 2015;16(10):4451-6. - PubMed
Xu 2009 {published data only}
    1. Xu KC, Niu LZ, Zhou Q, Hu YZ, Guo DH, Liu ZP, et al. Sequential use of transarterial chemoembolization and percutaneous cryosurgery for hepatocellular carcinoma. World Journal of Gastroenterology 2009;15(29):3664-9. - PMC - PubMed
Yang 2008 {published data only}
    1. Yang P, Liang M, Zhang Y, Shen B. Clinical application of a combination therapy of lentinan, multi-electrode RFA and TACE in HCC. Advances in Therapy 2008;25(8):787-94. - PubMed
Yin 2013 {published data only}
    1. Yin L. A prospective RCT comparing partial hepatectomy with TACE for multinodular HCC outside of Milan criteria. HPB : the Official Journal of the International Hepato Pancreato Biliary Association 2013;15:21-2.
Zhang 2011 {published data only}
    1. Zhang Q, Chen H, Li Q, Zang YJ, Chen XG, Zou WL, et al. Combination adjuvant chemotherapy with oxaliplatin, 5-fluorouracil and leucovorin after liver transplantation for hepatocellular carcinoma: a preliminary open-label study. Investigational New Drugs 2011;29(6):1360-9. - PubMed
Zhou 2009 {published data only}
    1. Zhou WP, Lai EC, Li AJ, Fu SY, Zhou JP, Pan ZY, et al. A prospective, randomized, controlled trial of preoperative transarterial chemoembolization for resectable large hepatocellular carcinoma. Annals of Surgery 2009;249(2):195-202. - PubMed

References to ongoing studies

NCT02854839 {published data only}
    1. Lee KG, Kyung T. A study of MG4101 (allogeneic natural killer cell) for intermediate-stage of hepatocellular carcinoma. clinicaltrials.gov/ct2/show/NCT02854839 Date first received: 2016.
Seinstra 2012 {published data only}
    1. Seinstra BA, Defreyne L, Lambert B, Lam M, Verkooijen HM, Erpecum KJ, et al. Transarterial radioembolization versus chemoembolization for the treatment of hepatocellular carcinoma (trace): study protocol for a randomized controlled trial. Trials 2012;13:144. - PMC - PubMed
    1. Seinstra BA, Defreyne L, Lambert B, Lam M, Verkooijen L, Van Erpecum KJ, et al. Transarterial radioembolization versus chemoembolization for the treatment of HCC: trace trial-an international multicenter randomized controlled trial. Journal of Vascular and Interventional Radiology 2012;23(3 Suppl):S150-1. - PMC - PubMed

Additional references

Arnaoutakis 2014
    1. Arnaoutakis DJ, Mavros MN, Shen F, Alexandrescu S, Firoozmand A, Popescu I, et al. Recurrence patterns and prognostic factors in patients with hepatocellular carcinoma in noncirrhotic liver: a multi-institutional analysis. Annals of Surgical Oncology 2014;21(1):147-54. - PMC - PubMed
Asham 2013
    1. Asham EH, Kaseb A, Ghobrial RM. Management of hepatocellular carcinoma. Surgical Clinics of North America 2013;93(6):1423-50. - PubMed
Bosetti 2014
    1. Bosetti C, Turati F, La Vecchia C. Hepatocellular carcinoma epidemiology. Best Practice & Research: Clinical Gastroenterology 2014;28(5):753-70. - PubMed
Bruix 2011
    1. Bruix J, Sherman M, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology (Baltimore, Md.) 2011;53(3):1020-2. - PMC - PubMed
Chaimani 2012
    1. Chaimani A, Salanti G. Using network meta-analysis to evaluate the existence of small-study effects in a network of interventions. Research Synthesis Methods 2012;3(2):161-76. - PubMed
Chaimani 2013
    1. Chaimani A, Higgins JP, Mavridis D, Spyridonos P, Salanti G. Graphical tools for network meta-analysis in STATA. PloS one 2013;8(10):e76654. - PMC - PubMed
Chan 2013a
    1. Chan AC, Cheung TT, Fan ST, Chok KS, Chan SC, Poon RT, et al. Survival analysis of high-intensity focused ultrasound therapy versus radiofrequency ablation in the treatment of recurrent hepatocellular carcinoma. Annals of Surgery 2013;257(4):686-92. - PubMed
Chan 2013b
    1. Chan A-W, Tetzlaff JM, Altman DG, Laupacis A, Gøtzsche PC, Krleža-Jerić K, et al. Spirit 2013 statement: defining standard protocol items for clinical trials. Annals of Internal Medicine 2013;158(3):200-7. - PMC - PubMed
Chen 2012
    1. Chen Y, Wang X, Wang J, Yan Z, Luo J. Excess body weight and the risk of primary liver cancer: an updated meta-analysis of prospective studies. European Journal of Cancer 2012;48(14):2137-45. - PubMed
Cillo 2006
    1. Cillo U, Vitale A, Grigoletto F, Farinati F, Brolese A, Zanus G, et al. Prospective validation of the Barcelona Clinic Liver Cancer staging system. Journal of Hepatology 2006;44(4):723-31. - PubMed
CLIP 1998
    1. The cancer of the liver Italian program (CLIP) investigators. A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators. Hepatology 1998;28(3):751-5. - PubMed
Davila 2004
    1. Davila JA, Morgan RO, Shaib Y, McGlynn KA, El-Serag HB. Hepatitis C infection and the increasing incidence of hepatocellular carcinoma: a population-based study. Gastroenterology 2004;127(5):1372-80. - PubMed
Del Re 2013
    1. Del Re AC, Spielmans GI, Flückiger C, Wampold BE. Efficacy of new generation antidepressants: differences seem illusory. PLoS One 2013;8(6):e63509. - PMC - PubMed
DeMets 1987
    1. DeMets DL. Methods for combining randomized clinical trials: strengths and limitations. Statistics in Medicine 1987;6(3):341-50. - PubMed
DerSimonian 1986
    1. DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clinical Trials 1986;7(3):177-88. - PubMed
Dias 2010
    1. Dias S, Welton NJ, Caldwell DM, Ades AE. Checking consistency in mixed treatment comparison meta-analysis. Statistics in Medicine 2010;29(7-8):932-44. - PubMed
Dias 2012a
    1. Dias S, Sutton AJ, Welton NJ, Ades AE. NICE DSU Technical Support Document 3: heterogeneity: subgroups, meta-regression, bias and bias-adjustment, September 2011 (last updated April 2012). www.nicedsu.org.uk/TSD3%20Heterogeneity.final%20report.08.05.12.pdf (accessed 27 March 2014).
Dias 2012b
    1. Dias S, Welton NJ, Sutton AJ, Ades AE. NICE DSU Technical Support Document 1: introduction to evidence synthesis for decision making, April 2011 (last updated April 2012). www.nicedsu.org.uk/TSD1%20Introduction.final.08.05.12.pdf (accessed 27 March 2014).
Dias 2014a
    1. Dias S, Welton NJ, Sutton AJ, Ades AE. NICE DSU Technical Support Document 2: a generalised linear modelling framework for pairwise and network meta-analysis of randomised controlled trials, August 2011 (last updated April 2014). www.nicedsu.org.uk/TSD2%20General%20meta%20analysis%20corrected%2015Apri... (accessed 8 October 2014). - PubMed
Dias 2014b
    1. Dias S, Welton NJ, Sutton AJ, Caldwell DM, Lu G, Ades AE. NICE DSU Technical Support Document 4: inconsistency in networks of evidence based on randomised controlled trials, May 2011 (last updated April 2014). www.nicedsu.org.uk/TSD4%20Inconsistency.final.15April2014.pdf (accessed 8 October 2014). - PubMed
EASL 2012
    1. European Association for Study of Liver, European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. Journal of Hepatology 2012;56(4):908-43. - PubMed
Egger 1997
    1. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ (Clinical Research Ed.) 1997;315(7109):629-34. - PMC - PubMed
EuroQol 2014
    1. EuroQol. About EQ-5D, 2014. www.euroqol.org/about-eq-5d.html (accessed 8 October 2014).
Forner 2014
    1. Forner A, Gilabert M, Bruix J, Raoul JL. Treatment of intermediate-stage hepatocellular carcinoma. Nature Reviews: Clinical Oncology 2014;11(9):525-35. - PubMed
Gaddikeri 2014
    1. Gaddikeri S, McNeeley MF, Wang CL, Bhargava P, Dighe MK, Yeh MMC, et al. Hepatocellular carcinoma in the noncirrhotic liver. American Journal of Roentgenology 2014;203(1):W34-47. - PubMed
Germani 2010
    1. Germani G, Pleguezuelo M, Gurusamy K, Meyer T, Isgro G, Burroughs AK. Clinical outcomes of radiofrequency ablation, percutaneous alcohol and acetic acid injection for hepatocellular carcinoma: a meta-analysis. Journal of Hepatology 2010;52(3):380-8. - PubMed
Germani 2011
    1. Germani G, Gurusamy K, Garcovich M, Toso C, Fede G, Hemming A, et al. Which matters most: number of tumors, size of the largest tumor, or total tumor volume? Liver Transplantation 2011;17(Suppl 2):S58-66. - PubMed
Gluud 2016
    1. Gluud C, Nikolova D, Klingenberg SL. Cochrane Hepato-Biliary Group. About Cochrane (Cochrane Review Groups (CRGs)) 2016, Issue 10. Art. No.: LIVER.
Guglielmi 2014
    1. Guglielmi A, Ruzzenente A, Conci S, Valdegamberi A, Vitali M, Bertuzzo F, et al. Hepatocellular carcinoma: surgical perspectives beyond the Barcelona Clinic Liver Cancer recommendations. World Journal of Gastroenterology 2014;20(24):7525-33. - PMC - PubMed
Gurusamy 2014
    1. Gurusamy KS, Nagendran M, Davidson BR. Methods of preventing bacterial sepsis and wound complications after liver transplantation. Cochrane Database of Systematic Reviews 2014, Issue 3. [DOI: 10.1002/14651858.CD006660.pub3] - DOI - PubMed
Guyatt 2011
    1. Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al. GRADE guidelines: 1. Introduction - GRADE evidence profiles and summary of findings tables. Journal of Clinical Epidemiology 2011;64(4):383-94. - PubMed
Head 2004
    1. Head HW, Dodd GD, 3rd. Thermal ablation for hepatocellular carcinoma. Gastroenterology 2004;127(5 Suppl 1):S167-78. - PubMed
Henderson 2003
    1. Henderson JM, Sherman M, Tavill A, Abecassis M, Chejfec G, Gramlich T. AHPBA/AJCC consensus conference on staging of hepatocellular carcinoma: consensus statement. HPB : the Official Journal of the International Hepato Pancreato Biliary Association 2003;5(4):243-50. - PMC - PubMed
Higgins 2011
    1. Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
Higgins 2012
    1. Higgins JPT, Jackson D, Barrett JK, Lu G, Ades AE, White IR. Consistency and inconsistency in network meta-analysis: Concepts and models for multi-arm studies. Research Synthesis Methods 2012;3(2):98-110. - PMC - PubMed
Hoffmann 2014
    1. Hoffmann R, Rempp H, Syha R, Ketelsen D, Pereira PL, Claussen CD, et al. Transarterial chemoembolization using drug eluting beads and subsequent percutaneous MR-guided radiofrequency ablation in the therapy of intermediate sized hepatocellular carcinoma. European Journal of Radiology 2014;83(10):1793-8. - PubMed
IARC 2014a
    1. International Agency for Research on Cancer. GLOBOCAN 2012: estimated cancer incidence, mortality, and prevalence worldwide in 2012. Liver cancer estimated incidence, mortality and prevalence worldwide in 2012. globocan.iarc.fr/Pages/fact_sheets_cancer.aspx (accessed 17 October 2014).
IARC 2014b
    1. International Agency for Research on Cancer. World 2012 (estimated cancer incidence, all ages: both sexes). globocan.iarc.fr/old/summary_table_pop-html.asp?selection=224900&title=W... (accessed 17 October 2014).
ICH‐GCP 1997
    1. International Conference on Harmonisation Expert Working Group. International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use. ICH harmonised tripartite guideline. Guideline for good clinical practice CFR & ICH Guidelines. Vol. 1. Philadelphia (PA): Barnett International/PAREXEL, 1997.
Jakobsen 2014
    1. Jakobsen JC, Wetterslev J, Winkel P, Lange T, Gluud C. Thresholds for statistical and clinical significance in systematic reviews with meta-analytic methods. BMC Medical Research Methodology 2014;14(1):120. - PMC - PubMed
Jepsen 2007
    1. Jepsen P, Vilstrup H, Tarone RE, Friis S, Sorensen HT. Incidence rates of hepatocellular carcinoma in the U.S. and Denmark: recent trends. International Journal of Cancer 2007;121(7):1624-6. - PubMed
Kansagara 2014
    1. Kansagara D, Papak J, Pasha AS, O'Neil M, Freeman M, Relevo R, et al. Screening for hepatocellular carcinoma in chronic liver disease: a systematic review. Annals of Internal Medicine 2014;161(4):261-9. - PubMed
Kjaergard 2001
    1. Kjaergard LL, Villumsen J, Gluud C. Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses. Annals of Internal Medicine 2001;135(11):982-9. - PubMed
Kollar 2014
    1. Kollar L, Rengan R. Stereotactic body radiotherapy. Seminars in Oncology 2014;41(6):776-89. - PubMed
Ladep 2014
    1. Ladep NG, Khan SA, Crossey MM, Thillainayagam AV, Taylor-Robinson SD, Toledano MB. Incidence and mortality of primary liver cancer in England and Wales: changing patterns and ethnic variations. World Journal of Gastroenterology 2014;20(6):1544-53. - PMC - PubMed
Lee 2009
    1. Lee YC, Cohet C, Yang YC, Stayner L, Hashibe M, Straif K. Meta-analysis of epidemiologic studies on cigarette smoking and liver cancer. International Journal of Epidemiology 2009;38(6):1497-511. - PubMed
Lencioni 2013
    1. Lencioni R, Petruzzi P, Crocetti L. Chemoembolization of hepatocellular carcinoma. Seminars in Interventional Radiology 2013;30(1):3-11. - PMC - PubMed
Liu 2012
    1. Liu Y, Chang CC, Marsh GM, Wu F. Population attributable risk of aflatoxin-related liver cancer: systematic review and meta-analysis. European Journal of Cancer 2012;48(14):2125-36. - PMC - PubMed
Llovet 1999
    1. Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Seminars in Liver Disease 1999;19(3):329-38. - PubMed
Llovet 2003
    1. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003;362(9399):1907-17. - PubMed
Lu 2006
    1. Lu G, Ades AE. Assessing evidence inconsistency in mixed treatment comparisons. Journal of the American Statistical Association 2006;101(474):447-59.
Lundh 2017
    1. Lundh A, Sismondo S, Lexchin J, Busuioc OA, Bero L. Industry sponsorship and research outcome. Cochrane Database of Systematic Reviews 2017, Issue 2. [DOI: 10.1002/14651858.MR000033.pub3] - DOI - PubMed
Macaskill 2001
    1. Macaskill P, Walter SD, Irwig L. A comparison of methods to detect publication bias in meta-analysis. Statistics in Medicine 2001;20(4):641-54. - PubMed
Maheshwari 2007
    1. Maheshwari S, Sarraj A, Kramer J, El-Serag HB. Oral contraception and the risk of hepatocellular carcinoma. Journal of Hepatology 2007;47(4):506-13. - PubMed
Majumdar 2017
    1. Majumdar A, Roccarina D, Thorburn D, Davidson BR, Tsochatzis E, Gurusamy KS. Management of people with early or very early stage hepatocellular carcinoma: a network meta-analysis. Cochrane Database of Systematic Reviews 2017, Issue 3. [DOI: 10.1002/14651858.CD011650.pub2] - DOI - PMC - PubMed
Mazzaferro 1996
    1. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. New England Journal of Medicine 1996;334(11):693-9. - PubMed
McDermott 2013
    1. McDermott S, Gervais DA. Radiofrequency ablation of liver tumors. Seminars in Interventional Radiology 2013;30(1):49-55. - PMC - PubMed
Miladinovic 2013
    1. Miladinovic J, Hozo I, Djulbegovic B. Trial sequential boundaries for cumulative meta-analyses. Stata Journal 2013;13(1):77-91.
Mills 2012
    1. Mills EJ, Ioannidis JP, Thorlund K, Schünemann HJ, Puhan MA, Guyatt GH. How to use an article reporting a multiple treatment comparison meta-analysis. JAMA 2012;308(12):1246-53. - PubMed
Moher 1998
    1. Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? Lancet 1998;352(9128):609-13. - PubMed
Nanashima 2006
    1. Nanashima A, Sumida Y, Abo T, Shindou H, Fukuoka H, Takeshita H, et al. Modified Japan Integrated Staging is currently the best available staging system for hepatocellular carcinoma patients who have undergone hepatectomy. Journal of Gastroenterology 2006;41(3):250-6. - PubMed
NCBI 2014
    1. NCBI. Carcinoma, hepatocellular, 2014. www.ncbi.nlm.nih.gov/mesh/68006528 (accessed 17 October 2014).
Newell 1992
    1. Newell DJ. Intention-to-treat analysis: implications for quantitative and qualitative research. International Journal of Epidemiology 1992;21(5):837-41. - PubMed
Nguyen 2009
    1. Nguyen KT, Gamblin TC, Geller DA. World review of laparoscopic liver resection - 2,804 patients. Annals of Surgery 2009;250(5):831-41. - PubMed
NHSBT 2014
    1. NHS Blood and Transplant. Organ donation. Activity report 2013-2014. www.organdonation.nhs.uk/statistics/transplant_activity_report/ (accessed 8 October 2014).
Niu 2016
    1. Niu M, Hong D, Ma TC, Chen XW, Han JH, Sun J, et al. Short-term and long-term efficacy of 7 targeted therapies for the treatment of advanced hepatocellular carcinoma: a network meta-analysis: Efficacy of 7 targeted therapies for AHCC. Medicine 2016;95(49):e5591. - PMC - PubMed
Okuda 1985
    1. Okuda K, Ohtsuki T, Obata H, Tomimatsu M, Okazaki N, Hasegawa H, et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer 1985;56(4):918-28. [PMID: ] - PubMed
Oliveri 2011
    1. Oliveri RS, Wetterslev J, Gluud C. Transarterial (chemo)embolisation for unresectable hepatocellular carcinoma. Cochrane Database of Systematic Reviews 2011, Issue 3. [DOI: 10.1002/14651858.CD004787.pub2] - DOI - PubMed
OpenBUGS 3.2.3 [Computer program]
    1. Members of OpenBUGS Project Management Group OpenBUGS. Version 3.2.3. Members of OpenBUGS Project Management Group, 2014.
OPTN 2014
    1. Organ Procurement and Transplantation Network. Policies, 2014. optn.transplant.hrsa.gov/ContentDocuments/OPTN_Policies.pdf (accessed on 17 October 2014).
Pleguezuelo 2008
    1. Pleguezuelo M, Marelli L, Misseri M, Germani G, Calvaruso V, Xiruochakis E, et al. TACE versus TAE as therapy for hepatocellular carcinoma. Expert Review of Anticancer Therapy 2008;8(10):1623-41. - PubMed
Pocobelli 2008
    1. Pocobelli G, Cook LS, Brant R, Lee SS. Hepatocellular carcinoma incidence trends in Canada: analysis by birth cohort and period of diagnosis. Liver International 2008;28(9):1272-9. - PubMed
Polesel 2009
    1. Polesel J, Zucchetto A, Montella M, Dal Maso L, Crispo A, La Vecchia C, et al. The impact of obesity and diabetes mellitus on the risk of hepatocellular carcinoma. Annals of Oncology 2009;20(2):353-7. - PubMed
Prasad 2011
    1. Prasad KR, Young RS, Burra P, Zheng SS, Mazzaferro V, Moon DB, et al. Summary of candidate selection and expanded criteria for liver transplantation for hepatocellular carcinoma: a review and consensus statement. Liver Transplantation 2011;17(Suppl 2):S81-9. - PubMed
Puhan 2014
    1. Puhan MA, Schünemann HJ, Murad MH, Li T, Brignardello-Petersen R, Singh JA, et al. A GRADE Working Group approach for rating the quality of treatment effect estimates from network meta-analysis. BMJ (Clinical Research Ed.) 2014;349:g5630. - PubMed
RevMan 2014 [Computer program]
    1. The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
Royle 2003
    1. Royle P, Milne R. Literature searching for randomized controlled trials used in Cochrane reviews: rapid versus exhaustive searches. International Journal of Technology Assessment in Health Care 2003;19(4):591-603. - PubMed
Salanti 2011
    1. Salanti G, Ades AE, Ioannidis JP. Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. Journal of Clinical Epidemiology 2011;64(2):163-71. - PubMed
Salanti 2012
    1. Salanti G. Indirect and mixed-treatment comparison, network, or multiple-treatments meta-analysis: many names, many benefits, many concerns for the next generation evidence synthesis tool. Research Synthesis Methods 2012;3(2):80-97. - PubMed
Sang 2013
    1. Sang LX, Chang B, Li XH, Jiang M. Consumption of coffee associated with reduced risk of liver cancer: a meta-analysis. BMC Gastroenterology 2013;13:34. - PMC - PubMed
Savović 2012a
    1. Savović J, Jones HE, Altman DG, Harris RJ, Jüni P, Pildal J, et al. Influence of reported study design characteristics on intervention effect estimates from randomized controlled trials: combined analysis of meta-epidemiological studies. Health Technology Assessment 2012;16(35):1-82. - PubMed
Savović 2012b
    1. Savović J, Jones HE, Altman DG, Harris RJ, Jüni P, Pildal J, et al. Influence of reported study design characteristics on intervention effect estimates from randomized controlled trials. Annals of Internal Medicine 2012;157(6):429-38. - PubMed
Schulz 1995
    1. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273(5):408-12. - PubMed
Schulz 2010
    1. Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. PLoS Medicine 2010;7(3):e1000251. - PMC - PubMed
Severini 1993
    1. Severini TA. Bayesian interval estimates which are also confidence intervals. Journal of the Royal Statistical Society. Series B (Methodological) 1993;55(2):533-40.
Sindram 2010
    1. Sindram D, Lau KN, Martinie JB, Iannitti DA. Hepatic tumor ablation. Surgical Clinics of North America 2010;90(4):863-76. - PubMed
SRTR 2012
    1. Scientific Registry of Transplant Recipients. OPTN/SRTR 2012 annual data report: liver. srtr.transplant.hrsa.gov/annual_reports/2012/pdf/03_liver_13.pdf (accessed 8 October 2014).
Starley 2010
    1. Starley BQ, Calcagno CJ, Harrison SA. Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology (Baltimore, Md.) 2010;51(5):1820-32. - PubMed
Stata/SE 14.2 [Computer program]
    1. Stata/SE 14.2 for Windows[64-bit x86-64]. Version 14. College Station: StataCorp LP, 2017.
Taura 2009
    1. Taura N, Yatsuhashi H, Nakao K, Ichikawa T, Ishibashi H. Long-term trends of the incidence of hepatocellular carcinoma in the Nagasaki prefecture, Japan. Oncology Reports 2009;21(1):223-7. - PubMed
Thorlund 2011
    1. Thorlund K, Engstrøm J, Wetterslev J, Brok J, Imberger G, Gluud C. User manual for Trial Sequential Analysis (TSA). ctu.dk/tsa/files/tsa_manual.pdf 2011 (accessed 29 November 2016).
Thorlund 2012
    1. Thorlund K, Mills EJ. Sample size and power considerations in network meta-analysis. Systematic Reviews 2012;1:41. - PMC - PubMed
TSA 2011 [Computer program]
    1. Copenhagen Trial Unit TSA - Trial Sequential Analysis. Version 0.9 Beta. Copenhagen: Copenhagen Trial Unit, 2011.www.ctu.dk/tsa/downloads.aspx.
Tsochatzis 2014
    1. Tsochatzis EA, Fatourou E, O'Beirne J, Meyer T, Burroughs AK. Transarterial chemoembolization and bland embolization for hepatocellular carcinoma. World Journal of Gastroenterology 2014;20(12):3069-77. - PMC - PubMed
Turati 2012
    1. Turati F, Edefonti V, Talamini R, Ferraroni M, Malvezzi M, Bravi F, et al. Family history of liver cancer and hepatocellular carcinoma. Hepatology (Baltimore, Md.) 2012;55(5):1416-25. - PubMed
Turati 2014
    1. Turati F, Galeone C, Rota M, Pelucchi C, Negri E, Bagnardi V, et al. Alcohol and liver cancer: a systematic review and meta-analysis of prospective studies. Annals of Oncology 2014;25(8):1526-35. - PubMed
Turner 2012
    1. Turner RM, Davey J, Clarke MJ, Thompson SG, Higgins JP. Predicting the extent of heterogeneity in meta-analysis, using empirical data from the Cochrane Database of Systematic Reviews. International Journal of Epidemiology 2012;41(3):818-27. - PMC - PubMed
Van Deusen 2005
    1. Van Deusen MA, Abdalla EK, Vauthey JN, Roh MS. Staging classifications for hepatocellular carcinoma. Expert Review of Molecular Diagnostics 2005;5(3):377-83. - PubMed
Van Malenstein 2011
    1. Van Malenstein H, Pelt J, Verslype C. Molecular classification of hepatocellular carcinoma anno 2011. European Journal of Cancer 2011;47(12):1789-97. - PubMed
van Valkenhoef 2012
    1. Valkenhoef G, Lu G, Brock B, Hillege H, Ades AE, Welton NJ. Automating network meta-analysis. Research Synthesis Methods 2012;3(4):285-99. - PubMed
Von Hahn 2011
    1. Von Hahn T, Ciesek S, Wegener G, Plentz RR, Weismuller TJ, Wedemeyer H, et al. Epidemiological trends in incidence and mortality of hepatobiliary cancers in Germany. Scandinavian Journal of Gastroenterology 2011;46(9):1092-8. - PubMed
Wan 2014
    1. Wan P, Yu X, Xia Q. Operative outcomes of adult living donor liver transplantation and deceased donor liver transplantation: a systematic review and meta-analysis. Liver Transplantation 2014;20(4):425-36. - PubMed
Ware 2014
    1. Ware JE. SF-36® health survey update, 2014. www.sf-36.org/tools/sf36.shtml (accessed on 8 October 2014).
Wetterslev 2008
    1. Wetterslev J, Thorlund K, Brok J, Gluud C. Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis. Journal of Clinical Epidemiology 2008;61(1):64-75. - PubMed
Witjes 2012
    1. Witjes CD, Karim-Kos HE, Visser O, den Akker SA, Vries E, Ijzermans JN, et al. Hepatocellular carcinoma in a low-endemic area: rising incidence and improved survival. European Journal of Gastroenterology and Hepatology 2012;24(4):450-7. - PubMed
Wood 2008
    1. Wood L, Egger M, Gluud LL, Schulz KF, Jüni P, Altman DG, et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. BMJ (Clinical Research Ed.) 2008;336(7644):601-5. - PMC - PubMed
Wu 1996
    1. Wu PC, Fang JW, Lau VK, Lai CL, Lo CK, Lau JY. Classification of hepatocellular carcinoma according to hepatocellular and biliary differentiation markers. Clinical and biological implications. American Journal of Pathology 1996;149(4):1167-75. - PMC - PubMed
Xiong 2012
    1. Xiong JJ, Altaf K, Javed MA, Huang W, Mukherjee R, Mai G, et al. Meta-analysis of laparoscopic vs open liver resection for hepatocellular carcinoma. World Journal of Gastroenterology 2012;18(45):6657-68. - PMC - PubMed
Yang 2014
    1. Yang Y, Zhang D, Feng N, Chen G, Liu J, Chen G, et al. Increased intake of vegetables, but not fruit, reduces risk for hepatocellular carcinoma: a meta-analysis. Gastroenterology 2014;147(5):1031-42. - PubMed

MeSH terms

LinkOut - more resources